Wockhardt share price
NSE: WOCKPHARMABSE: 532300Pharmaceuticals & BiotechnologySmall Cap
Wockhardt Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹1,913.40up ₹28.60 (1.52%)BSE ₹1,912.70
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,884.80.
28 Oct: open ₹1,885.00, high ₹1,934.00, low ₹1,861.20
52-week range of traded prices to 28 Oct 2026
₹1,086.70Low, 23 Mar 2026₹2,422.30High, 1 Jun 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹31,091 Cr311th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 76.02
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.29
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,90,59638.2% delivered
About Wockhardt
Wockhardt Limited is a pharmaceutical and biotechnology company that discovers new antibiotics, makes insulin biosimilars (close copies of insulin medicines made in living cells) and sells branded and specialty medicines.1 Its antibiotic research targets antimicrobial resistance, where germs no longer respond to existing drugs, and its biosimilars target diabetes.2 It is based in Mumbai.3
It reports a single pharmaceutical segment, which management describes as 3 pillars: pharmaceuticals, biosimilars and biotech, and novel antibiotics.45 Its brands include the antibiotics Zaynich, Miqnaf, Emrok and Emrok O, the insulins Wosulin and Glaritus, and the insulin pens DispoPen and Mypen.678 It makes medicines in India, the UK, Ireland and Dubai, and has a presence in Switzerland and other countries.9 Its main subsidiaries are Wockhardt Bio AG, an 85.85%-owned Swiss company that distributes its products in the UK and Europe, CP Pharmaceuticals, Wockhardt UK, Wockpharma Ireland and Pinewood Laboratories.101112
It was incorporated in 1999.3 In 2020 it transferred part of its Indian branded business to Dr.Reddy's Laboratories.13 As part of its exit from US generic medicines, it filed in July 2025 for voluntary liquidation of its US subsidiaries Morton Grove Pharmaceuticals and Wockhardt USA.14
Habil Khorakiwala is the founder chairman, and Themisto Trustee Company, holding shares for the Habil Khorakiwala Trust through the partnership firm Humuza Consultants, owned 40.15% of the company at the end of March 2026.1516 His children Murtaza, Huzaifa and Zahabiya Khorakiwala are the managing director, an executive director and a director.2
Wockhardt key points
Results
- In the year to Mar 2026, consolidated revenue from operations rose 12% to ₹3,373 crore from ₹3,012 crore.17
- In the year to Mar 2026, EBITDA (earnings before interest, tax, depreciation and amortisation) rose 51% to ₹630 crore from ₹418 crore, an EBITDA margin of 18.6%, and profit before tax was ₹238 crore.1819
- In the year to Mar 2026, profit attributable to shareholders, after the minority owners' share, was about 6.3% of revenue, against a loss of about 1.5% a year earlier.1920
- Profit for the year to Mar 2026 includes one-off items of ₹110 crore, the net impact of removing its US subsidiaries from the group accounts, and ₹10 crore for India's new labour codes.21
Revenue mix
- Management said on 4 Jun 2026 that pharmaceuticals make up about 75% of the business; novel antibiotics and biosimilars contributed 23% of revenue in the year to Mar 2026.2223
- The biosimilars and biotech business grew 27% to ₹697 crore in the year to Mar 2026.2425
- Management said on 4 Jun 2026 that the biosimilars business has 2 products on sale and 5 in development, including semaglutide, and is registered in 30 emerging markets.26
Where revenue comes from
- In the year to Mar 2026, the UK business grew 13% to ₹1,318 crore from ₹1,169 crore, about 39% of revenue.27
- In the year to Mar 2026, the rest-of-world business grew 35% to ₹958 crore from ₹710 crore; India was ₹740 crore and the EU ₹356 crore, 11% of revenue.28
- Management said on 4 Jun 2026 that the UK and Ireland make up about 50% of the business and that it holds 18% of what it called its covered UK market.2930
Plants and capacity
Research and development
- The company holds 6 Qualified Infectious Disease Product designations from the US FDA, a status for new antibiotics against serious infections, one for each antibiotic in clinical development.33
- In a Phase 3 (late-stage) trial of 530 patients at 64 sites, Zaynich had a combined clinical cure and microbiological response rate of 89.0% in complicated urinary tract infections, against 68.4% for meropenem, an older antibiotic.34
- In a Phase 3 trial, the antibiotic Foviscu had a clinical cure rate of 93.23% against 92.31% for meropenem. On 25 Mar 2026, India's drug regulator's expert committee approved a Phase 2 trial plan for Odrate in complicated urinary tract infections.3536
- By the end of March 2026, the company had filed 3,290 patents and been granted 859.37
What the company expects
- The company said on 4 Jun 2026 that it expects global revenue from Zaynich of about $1.5 billion to $2 billion.38
- The company said on 4 Jun 2026 that it expects European approval for Zaynich by the end of the year, and aims to register and launch in 7 to 8 emerging markets with high carbapenem resistance (germs resisting last-line antibiotics) in 18 to 24 months.3940
- The company said on 4 Jun 2026 that it expects to double the biosimilars business within 24 to 36 months and double its biosimilars capacity within 12 to 15 months.41
- The company said on 4 Jun 2026 that it expects capital spending of about ₹200 crore to ₹300 crore over the next 3 years, mainly on biologicals capacity (medicines made in living cells).42
Recent events
- On 30 May 2026, the company announced US FDA approval of Zaynich, the first new chemical entity fully developed and commercialized by an Indian drug company to win FDA approval, it says; India's regulator approved it on 27 May 2026.4344
- On 21 May 2026, ICRA upgraded the company's term loan rating, its view of the ability to repay, to A- (Stable) from BBB (Positive).45
- On 4 May 2026, the board proposed raising up to ₹3,000 crore through shares or other securities, subject to shareholder approval at the AGM of 10 Aug 2026; the company's documents give no outcome.4647
- Effective 31 Mar 2026, the company settled all claims with Dr.Reddy's Laboratories over the business it had sold to it, recording a net gain of ₹35 crore.48
Litigation and regulatory matters
- On 21 Aug 2026, the company received an order of the Commissioner of Customs, Nhava Sheva, imposing a ₹5,00,00,000 penalty and a ₹10,00,00,000 redemption fine over a misdeclared drug ingredient; on 25 Aug 2026 it said it is taking steps to appeal.4950
- At the end of March 2026, the company was disputing a ₹136 crore demand from the National Pharmaceutical Pricing Authority over alleged overcharging, and income tax demands of ₹345 crore.51
Last updated
All 51 sources, each with its page
- 1. Investor presentation, 4 Jun 2026, page 7
- 2. Annual report, 17 Jul 2026, page 27
- 3. Annual report, 17 Jul 2026, page 2
- 4. Annual report, 17 Jul 2026, page 140
- 5. Earnings call, 4 Jun 2026, page 3
- 6. Annual report, 17 Jul 2026, page 61
- 7. Annual report, 17 Jul 2026, page 27
- 8. Annual report, 17 Jul 2026, page 62
- 9. Annual report, 17 Jul 2026, page 106
- 10. Annual report, 17 Jul 2026, page 32
- 11. Annual report, 17 Jul 2026, page 195
- 12. Annual report, 17 Jul 2026, page 313
- 13. Annual report, 17 Jul 2026, page 208
- 14. Annual report, 17 Jul 2026, page 147
- 15. Annual report, 17 Jul 2026, page 45
- 16. Annual report, 17 Jul 2026, page 200
- 17. Annual report, 17 Jul 2026, page 28
- 18. Earnings call, 4 Jun 2026, page 4
- 19. Annual report, 17 Jul 2026, page 27
- 20. Annual report, 17 Jul 2026, page 78
- 21. Annual report, 17 Jul 2026, page 147
- 22. Earnings call, 4 Jun 2026, page 3
- 23. Investor presentation, 4 Jun 2026, page 9
- 24. Annual report, 17 Jul 2026, page 49
- 25. Earnings call, 4 Jun 2026, page 4
- 26. Earnings call, 4 Jun 2026, page 5
- 27. Annual report, 17 Jul 2026, page 28
- 28. Annual report, 17 Jul 2026, page 28
- 29. Earnings call, 4 Jun 2026, page 20
- 30. Earnings call, 4 Jun 2026, page 5
- 31. Investor presentation, 4 Jun 2026, page 7
- 32. Investor presentation, 4 Jun 2026, page 9
- 33. Annual report, 17 Jul 2026, page 27
- 34. Exchange filing, 30 May 2026, page 3
- 35. Annual report, 17 Jul 2026, page 88
- 36. Annual report, 17 Jul 2026, page 88
- 37. Annual report, 17 Jul 2026, page 88
- 38. Earnings call, 4 Jun 2026, page 22
- 39. Earnings call, 4 Jun 2026, page 18
- 40. Investor presentation, 4 Jun 2026, page 33
- 41. Earnings call, 4 Jun 2026, page 26
- 42. Earnings call, 4 Jun 2026, page 15
- 43. Exchange filing, 30 May 2026, page 2
- 44. Exchange filing, 30 May 2026, page 3
- 45. Exchange filing, 21 May 2026, page 1
- 46. Annual report, 17 Jul 2026, page 19
- 47. Annual report, 17 Jul 2026, page 1
- 48. Annual report, 17 Jul 2026, page 208
- 49. Exchange filing, 25 Aug 2026, page 2
- 50. Exchange filing, 25 Aug 2026, page 1
- 51. Annual report, 17 Jul 2026, page 159
Results
Consolidated; ₹ crore.Wockhardt quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +18.4%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹929 Crdown 3.73%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹107 Crdown 34.76%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 11.5%
Revenue by quarter
Peak revenue ₹965 Cr, quarter to Mar 2026; lowest ₹721 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 3 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 809 | 721 | 743 | 738 | 782 | 888 | 965 | 929 |
| Net profit | −16 | 20 | −45 | −108 | 82 | 61 | 164 | 107 |
| Net margin | −2.0% | 2.8% | −6.1% | −14.6% | 10.5% | 6.9% | 17.0% | 11.5% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹3,373 Crup 11.99%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹199 CrYear to Mar 2025: −₹57 Cr
- Net margin
- 5.9%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
Back to profit in the year to Mar 2026, ₹199 CrA loss in 8 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2020, the company's revenue for that year, ₹2,844 Cr, differs from its quarters added, ₹3,221 Cr; the company reports a discontinued business.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,015 | 3,937 | 4,158 | 2,844 | 2,708 | 3,230 | 2,651 | 2,798 | 3,012 | 3,373 |
| Net profit | −196 | −725 | −217 | −43 | 689 | −279 | −621 | −472 | −57 | 199 |
| Net margin | −4.9% | −18.4% | −5.2% | – | – | −8.6% | −23.4% | −16.9% | −1.9% | 5.9% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. Net margin is left blank for Mar 2020 and Mar 2021: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2020: days before it are of the company before the change.Wockhardt PE ratio and valuation
Price to earnings
At or below today's level on 12% of 176 trading days over the last year.
LowestHighest
Its median103.52Industry median28.10
Price to book
At or below today's level on 95% of 1,735 trading days since Nov 2018.
LowestHighest
Its median1.57Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 90% of 2,459 trading days over the last 10 years.
LowestHighest
Its median0.00%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −17.5% | – | – | 0.0% |
| 3 years | +96.9% | – | – | 0.0% |
| 5 years | +23.2% | −26.7% | +68.1% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2021 and Mar 2026.
Mutual fund holdings
85 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 52 of the 58 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 85 funds holding Wockhardt
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 23
- CutCut. Funds that held fewer shares than at the end of the month before.
- 35
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 25
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 1
| Fund | |||
|---|---|---|---|
 Tata Small Cap FundTata Mutual Fund | 21,00,000 | 3.36% | ₹444.4 Cr |
 HSBC Small Cap FundHSBC Mutual Fund | 11,82,445 | 1.35% | ₹250.2 Cr |
| Tata Large & Mid Cap FundTata Mutual Fund | 9,78,826 | 2.86% | ₹207.1 Cr |
 Invesco India Contra FundInvesco Mutual Fund | 6,57,574 | 0.72% | ₹139.2 Cr |
 Bandhan Small Cap FundBandhan Mutual Fund | 5,22,354 | 0.31% | ₹110.5 Cr |
| HSBC Flexi Cap FundHSBC Mutual Fund | 3,58,818 | 1.32% | ₹75.9 Cr |
 Bank of India Small Cap FundBank of India Mutual Fund | 3,50,000 | 2.02% | ₹74.1 Cr |
 ITI Small Cap FundITI Mutual Fund | 3,29,595 | 1.90% | ₹69.8 Cr |
 HDFC Large & Mid Cap FundHDFC Mutual Fund | 3,27,653 | 0.24% | ₹69.3 Cr |
| HDFC Manufacturing fundHDFC Mutual Fund | 3,00,000 | 0.62% | ₹63.5 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Wockhardt insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 30 pledge filings of unclear kind
- Others: no market trade · 4 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Wockhardt competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Wockhardt in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Ajanta PharmaAJANTPHARM | 43,233 | 38.10 | 9.55 | +20.2% | +22.0% | 27.3% | 27.2% | 1.73% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 42,318 | 39.62 | 18.66 | +5.8% | +12.4% | 50.6% | 56.3% | 2.28% |
 Emcure PharmaceuticalsEMCURE | 35,571 | 35.17 | 7.19 | +18.4% | +35.9% | 21.5% | 25.2% | 0.19% |
 Sai Life SciencesSAILIFE | 31,591 | 87.33 | 12.72 | – | – | 15.7% | 18.7% | 0.00% |
 Piramal PharmaPPLPHARMA | 30,994 | – | 3.81 | +9.4% | – | −2.6% | 2.3% | 0.00% |
 Acutaas ChemicalsACUTAAS | 30,374 | 69.17 | 16.35 | +45.2% | +96.1% | 26.9% | 30.2% | 0.07% |
 Rubicon ResearchRUBICON | 25,889 | 89.83 | 20.09 | – | – | 22.4% | 25.8% | 0.10% |
 Neuland LaboratoriesNEULANDLAB | 25,621 | 51.47 | 13.67 | +78.3% | +182.6% | 29.3% | 32.1% | 0.17% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Wockhardt dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹10.00 a share, year to Mar 2017.
| Ex-date | Type | Per share |
|---|---|---|
| 17 Nov 2016 | Interim | ₹10.00 |
| 13 Nov 2014 | Interim | ₹20.00 |
| 17 Feb 2014 | Interim | ₹5.00 |
| 7 Nov 2013 | Interim | ₹5.00 |
| 22 Aug 2013 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹5.00 |
| 17 Apr 2008 | Final | ₹2.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Wockhardt announcements
Oct 2026
27 Oct · Board meeting
Aug 2026
Wockhardt share price by year
Each calendar year to 2025.Wockhardt share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,446.20 | +2.1% | 1,831.10 | 1,155.50 |
| 2024 | 1,416.85 | +233.9% | 1,531.10 | 422.85 |
| 2023 | 424.35 | +90.2% | 424.35 | 149.30 |
| 2022 | 223.05 | −46.0% | 438.40 | 205.65 |
| 2021 | 412.85 | −24.5% | 786.65 | 390.05 |
| 2020 | 546.55 | +133.6% | 550.50 | 156.20 |
| 2019 | 233.95 | −55.3% | 528.75 | 233.65 |
| 2018 | 523.25 | −43.8% | 992.85 | 446.30 |
| 2017 | 931.35 | +41.6% | 931.35 | 538.05 |
| 2016 | 657.75 | −57.0% | 1,619.35 | 636.20 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 1,814.80 | 1,893.00 | 1,805.00 | 1,884.80 | 1,867.37 | 5,24,659 | 41.7% |
| 26 Oct 2026 | 1,795.00 | 1,834.00 | 1,780.50 | 1,809.60 | 1,809.06 | 7,98,653 | 44.9% |
| 23 Oct 2026 | 1,857.00 | 1,864.00 | 1,772.00 | 1,801.70 | 1,803.25 | 8,79,190 | 43.6% |
| 22 Oct 2026 | 1,872.00 | 1,899.90 | 1,846.00 | 1,855.50 | 1,868.97 | 4,57,019 | 31.7% |
| 21 Oct 2026 | 1,920.90 | 1,926.00 | 1,858.00 | 1,877.20 | 1,887.75 | 4,71,545 | 40.2% |
| 19 Oct 2026 | 1,963.70 | 1,966.00 | 1,900.60 | 1,906.30 | 1,926.68 | 3,60,528 | 43.8% |
| 16 Oct 2026 | 1,957.00 | 1,985.50 | 1,941.10 | 1,954.90 | 1,965.40 | 4,48,312 | 42.6% |
| 15 Oct 2026 | 1,988.00 | 1,988.00 | 1,931.20 | 1,949.40 | 1,961.20 | 4,10,296 | 42.9% |
| 14 Oct 2026 | 1,986.00 | 2,003.90 | 1,960.40 | 1,986.10 | 1,984.78 | 4,83,873 | 41.8% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Rights issue history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 8 Mar 2022 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 24 Aug 2015 | Price move | – | Between two trading sessions the price moved by a fifth or more. The Nifty 500 moved 5% or more the same way over the same sessions. Not adjusted for. |
| 23 May 2013 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
Each event is noted and not adjusted for.
Company details
- NSE symbol
- WOCKPHARMA
- BSE code
- 532300
- ISIN
- INE049B01025
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.wockhardt.com
- CIN
- L24230MH1999PLC120720
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1999
- Registered office
- Wockhardt Research Centre,, D - 4, MIDC, Chikalthana, Aurangabad 431006, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, Nifty Smallcap 100, BSE SmallCap